Synapse - Works

Results (5611)

Ibrutinib for the treatment of Bing‐Neel syndrome: A retrospective, multicenter study

Meeting Abstract

Castillo, J.; Itchaki, G.; Paludo, J.; Varettoni, M.; Buske, C.; Eyre, T.; Chavez, J.; Shain, K.; Issa, S.; Palomba, L.; more...
Hematological Oncology (2019)

Fulltext@MSK | Save

Ibrutinib monotherapy produces long‐term disease control in previously treated Waldenstrom's macroglobulinemia. Final report of the pivotal trial (NCT01614821)

Meeting Abstract

Treon, S. P.; Meid, K.; Gustine, J.; Yang, G.; Xu, L.; Patterson, C. J.; Ghobrial, I.; Laubach, J. P.; Hunter, Z. R.; Dubeau, T.; more...
Hematological Oncology (2019)

Fulltext@MSK | Save

Phase I clinical trial of CD19‐targeted 19‐28z/4‐1BBL "armored" CAR T cells in patients with relapsed or refractory NHL and CLL including Richter transformation

Meeting Abstract

Batlevi, C. L.; Palomba, M. L.; Park, J.; Mead, E.; Santomasso, B.; Riviere, I.; Wang, X.; Senechal, B.; Furman, R.; Yang, J.; more...
Hematological Oncology (2019)

Fulltext@MSK | Save

Impact of pet imaging and histologic transformation on the prognosis of early disease progression in follicular lymphoma

Meeting Abstract

Batlevi, C. L.; Sha, F.; Alperovich, A.; Ni, A.; Smith, K.; Ying, Z.; Hamlin, P.; Horwitz, S. M.; Kumar, A.; Matasar, M.; more...
Hematological Oncology (2019)

Fulltext@MSK | Save

Concordance between immunohistochemistry and gene expression profiling subtyping for diffuse large B‐cell lymphoma in the phase 3 PHOENIX trial

Meeting Abstract

Balasubramanian, S.; Wang, S.; Major, C.; Hodkinson, B.; Schaffer, M.; Sehn, L. H.; Johnson, P.; Zinzani, P. L.; Carey, J.; Liu, G.; more...
Hematological Oncology (2019)

Fulltext@MSK | Save

Nivolumab combined with brentuximab vedotin for relapsed/refractory primary mediastinal large B‐cell lymphoma: Efficacy and safety from the phase 2 CheckMate 436 study

Meeting Abstract

Zinzani, P. L.; Santoro, A.; Gritti, G.; Brice, P.; Barr, P. M.; Kuruvilla, J.; Cunningham, D.; Kline, J.; Johnson, N. A.; Mehta‐Shah, N. A.; more...
Hematological Oncology (2019)

Fulltext@MSK | Save

A phase 2 study to assess the safety and efficacy of umbralisib in patients with chronic lymphocytic leukemia (CLL) who are intolerant to prior BTK or PI3K delta inhibitor therapy

Meeting Abstract

Mato, A. R.; Schuster, S. J.; Lamanna, N.; Pagel, J. M.; Flinn, I. W.; Barrientos, J.; Reeves, J. A.; Cheson, B. D.; Barr, P. M.; Kambhampati, S.; more...
Hematological Oncology (2019)

Fulltext@MSK | Save

Analysis of clinical determinants driving safety and efficacy of camidanlumab tesirine (ADCT‐301, Cami) in relapsed/refractory (R/R) classical Hodgkin lymphoma (CHL)

Meeting Abstract

Collins, G.; Horwitz, S.; Hamadani, M.; Samaniego, F.; Spira, A.; Caimi, P.; Davies, A.; Menne, T.; Fields, P.; Cruz, H.; more...
Hematological Oncology (2019)

Fulltext@MSK | Save

Efficacy and safety of obinutuzumab + lenalidomide + atezolizumab in patients with relapsed or refractory follicular lymphoma: Primary analysis of a phase 1b/2 trial

Meeting Abstract

Morschhauser, F.; Ghosh, N.; Lossos, I.; Palomba, M. L.; Mehta, A.; Casasnovas, O.; Stevens, D.; Chitra, S.; Knapp, A.; Nielsen, T.; more...
Hematological Oncology (2019)

Fulltext@MSK | Save

Phase I/II study of umbralisib (TGR‐1202) in combination with ublituximab (TG‐1101) and pembrolizumab in patients with REL/REF CLL and Richter's transformation

Meeting Abstract

Mato, A. R.; Svoboda, J.; Luning Prak, E. T.; Schuster, S. J.; Tsao, P. Y.; Dorsey, C.; Sarmasti, L. M.; Becker, P. S.; Brander, D. M.; Nasta, S.; more...
Hematological Oncology (2019)

Fulltext@MSK | Save